Azacitidine - Revision history

Prab at 08:12, 21 March 2025

2025-03-21T08:12:41Z

← Older revision		Revision as of 08:12, 21 March 2025
Line 1:		Line 1:
			[[File:Azacitidine.svg\|Azacitidine\|thumb]]
	'''azacitidine''' (ay-zuh-SY-tih-deen) is a drug used to treat myelodysplastic syndromes. It is also being studied in the treatment of other conditions and types of [[cancer]].		'''azacitidine''' (ay-zuh-SY-tih-deen) is a drug used to treat myelodysplastic syndromes. It is also being studied in the treatment of other conditions and types of [[cancer]].

Line 21:		Line 22:
	{{cancer drugs}}		{{cancer drugs}}
	{{coststubd}}		{{coststubd}}
	~~<gallery>~~		{{Chemotherapeutic agents}}
	~~File~~:~~Azacitidine.svg\|Azacitidine~~		{{Portal bar \| Medicine}}
	~~</gallery>~~		[[Category:Drugs developed by Bristol Myers Squibb]]
	~~<gallery>~~		[[Category:Nucleosides]]
	~~File~~:~~Azacitidine.svg\|Azacitidine~~		[[Category:Triazines]]
	~~</gallery>~~		[[Category:Lactams]]
			[[Category:Orphan drugs]]
			[[Category:IARC Group 2A carcinogens]]
			[[Category:Pyrimidine antagonists]]
			[[Category:Suspected male-mediated teratogens]]
			{{nt}}

Prab: CSV import

2025-02-20T00:44:55Z

CSV import

← Older revision		Revision as of 00:44, 20 February 2025
Line 21:		Line 21:
	{{cancer drugs}}		{{cancer drugs}}
	{{coststubd}}		{{coststubd}}
			<gallery>
			File:Azacitidine.svg\|Azacitidine
			</gallery>
	<gallery>		<gallery>
	File:Azacitidine.svg\|Azacitidine		File:Azacitidine.svg\|Azacitidine
	</gallery>		</gallery>

Prab: CSV import

2025-02-20T00:42:37Z

CSV import

← Older revision		Revision as of 00:42, 20 February 2025
Line 21:		Line 21:
	{{cancer drugs}}		{{cancer drugs}}
	{{coststubd}}		{{coststubd}}
			<gallery>
			File:Azacitidine.svg\|Azacitidine
			</gallery>

Prab at 21:03, 18 April 2019

2019-04-18T21:03:52Z

New page

'''azacitidine''' (ay-zuh-SY-tih-deen) is a drug used to treat myelodysplastic syndromes. It is also being studied in the treatment of other conditions and types of [[cancer]].

==How does it work?==
Azacitidine stops cells from making DNA and may kill abnormal blood cells or [[cancer]] cells. It is a type of antimetabolite. Also called [[Vidaza]].

{{livtox}}
Azacitidine is associated with a low rate of transient serum enzyme elevations during therapy and has only rarely been implicated in cases of clinically apparent acute [[liver injury]] with jaundice.

{{moa}}
Azacitidine (ay" za sye' ti deen: also spelled azacytidine) is a pyrimidine analogue (5-azacytidine) which is converted intracellularly to a triphosphate which becomes incorporated into [[RNA]] and [[DNA]]. While azacitidine has [[anticancer]] effects, it proved to have limited usefulness in solid tumors and [[lymphoma]]s. In low doses, azacitidine inhibits methylation of [[DNA]] and results in the expression of silenced genes, including tumor suppressor genes. Studies done in vitro and in vivo have shown that azacitidine induces differentiation of bone marrow cells and results in normalization of bone marrow in a proportion of patients with myelodysplasia.

{{fda}}
Azacitidine was approved for use in the United States in 2004 and the current single indication is for therapy of myelodysplastic syndromes. It is also under evaluation as therapy of acute myelogenous [[leukemia]]. Azacitidine is available as a powder for injection in 100 mg vials under the trade name of Vidaza. An oral formulation is currently under evaluation.

{{dose}}
The usual initial dosage regimen in adults is 75 mg per meter-squared body surface area subcutaneously each day for 7 days, with repeat courses after 28 days. A minimum of 4 courses is recommended and the dose can be increased based upon tolerance and response.

{{se}}
Common [[side effects]] include [[bone marrow suppression]], [[nausea]], [[vomiting]], [[diarrhea]], stomatitis, bruising, abdominal pain, myalgias, [[headache]], [[dizziness]], [[fatigue]], [[fever]], rash and pruritus.

{{cancer drugs}}
{{coststubd}}